Loading
Wasting has several causes. Measuring the specific hormone in each patient's blood would put the right patients into the right trial instead of mixing everyone together.
Cachexia trials have historically enrolled by weight loss criteria alone, mixing inflammatory, anorexic, hypermetabolic and mechanical causes. Plasma GDF-15, interleukin-6, C-reactive protein and resting energy expenditure define mechanistically distinct groups. Enriching for high GDF-15 in anti-GDF-15 trials, and for high interleukin-6 in anti-inflammatory trials, is straightforward and cheap.
Shares Ponsegromab phase 2 in cancer cachexia, Cachexia, toxicity and the limits of the patient, Pancreatic ductal adenocarcinoma, Non-small-cell lung cancer.
Shares Proteomics & phosphoproteomics, Non-small-cell lung cancer.
Shares Ponsegromab phase 2 in cancer cachexia, Cachexia, toxicity and the limits of the patient, Pancreatic ductal adenocarcinoma, Non-small-cell lung cancer.
Shares Proteomics & phosphoproteomics, Biomarkers are not validated or standardised, Pancreatic ductal adenocarcinoma.
Shares Cachexia, toxicity and the limits of the patient, Trial design, endpoints and cost.
Shares Cachexia, toxicity and the limits of the patient, Pancreatic ductal adenocarcinoma, Non-small-cell lung cancer.
Shares Proteomics & phosphoproteomics, Non-small-cell lung cancer.
Shares Cachexia, toxicity and the limits of the patient, Pancreatic ductal adenocarcinoma, Non-small-cell lung cancer.